TOPG:TASETop Group Software Ltd. Analysis
Data as of 2026-03-17 - not real-time
MYR 0.58
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Top Glove (TOPG) is trading at MYR 0.58, well below its 20‑day (0.576), 50‑day (0.600) and 200‑day (0.641) moving averages, signalling a bearish price bias. The RSI sits at 49.9, indicating a neutral momentum, while the MACD has turned mildly bullish (line above signal) and volume is trending higher, suggesting a possible short‑term bounce off the support around MYR 0.53. However, the stock’s PE of 29 exceeds the industry average of 26.4 and the DCF‑derived fair value of MYR 0.426, implying the market is pricing in a premium despite modest revenue growth (‑0.3%) and thin margins (gross 15%, operating 5.5%).
Financially, Top Glove carries a high debt load (debt‑to‑equity ~17.9) relative to its cash position, and returns are weak (ROE 2.7%). Volatility is elevated at 35% over the past 30 days, though beta remains low (0.35), tempering systematic risk. The dividend yield is modest at 0.81% with a payout ratio under 30%, making the payout sustainable but not a core attraction. Overall, the stock appears overvalued in the near term, but its defensive healthcare exposure and modest dividend could support a longer‑run hold stance.
Financially, Top Glove carries a high debt load (debt‑to‑equity ~17.9) relative to its cash position, and returns are weak (ROE 2.7%). Volatility is elevated at 35% over the past 30 days, though beta remains low (0.35), tempering systematic risk. The dividend yield is modest at 0.81% with a payout ratio under 30%, making the payout sustainable but not a core attraction. Overall, the stock appears overvalued in the near term, but its defensive healthcare exposure and modest dividend could support a longer‑run hold stance.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below all major moving averages
- Support level near current price
- Elevated short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Potential earnings improvement if glove demand stabilises
- High debt burden limiting upside
- Valuation still above DCF fair value
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Defensive healthcare exposure
- Sustainable dividend despite low yield
- Opportunity for debt deleveraging and valuation convergence
Key Metrics & Analysis
Financial Health
Revenue Growth-0.30%
Profit Margin4.29%
P/E Ratio29.0
ROE2.73%
ROA0.44%
Debt/Equity17.86
P/B Ratio1.0
Op. Cash FlowMYR439.5M
Free Cash FlowMYR262.2M
Industry P/E26.4
Technical Analysis
TrendBearish
RSI49.9
SupportMYR 0.53
ResistanceMYR 0.61
MA 20MYR 0.58
MA 50MYR 0.60
MA 200MYR 0.64
MACDBullish
VolumeIncreasing
Fear & Greed Index79.45
Valuation
Fair ValueMYR 0.43
Target PriceMYR 0.70
Upside/Downside20.37%
GradeOvervalued
TypeValue
Dividend Yield0.81%
Risk Assessment
Beta0.35
Volatility35.03%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.